CRRT for Glutamate Elimination After Cardiac Arrest

Reperfusion Syndrome Clinical Trial

— GCRRT  

Official title:

Pilot Trial Concerning Glutamate Elimination With CRRT for Neurological Outcome After Cardiac Arrest

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02963298
• Other study ID #: Glu2016
• Status: Completed
• Phase: N/A
• Start date: October 2016
• Est. completion date: September 6, 2017

Study information

• Verified date: June 2019
• Source: Charite University, Berlin, Germany
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Glutamate is known to be a mediator for apoptosis after brain hypoxia e.g. due to cardiac arrest. This pilot trial evaluates the possibility of elimination of Glutamate by CRRT after cardiac arrest.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 42
• Est. completion date: September 6, 2017
• Est. primary completion date: September 6, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• post cardiac arrest

Exclusion Criteria:

• hemodynamic instable

• in-hospital cardiac arrest

Related Conditions & MeSH terms

• Heart Arrest
• Reperfusion Syndrome

Intervention

Procedure:
• Continuous renal replacement therapy

Locations

Country	Name	City	State
Germany	Charité-Universitätsmedizin Berlin	Berlin

Sponsors (1)

Lead Sponsor	Collaborator
C. Storm

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Glutamate blood concentration in intervention arm over the time	Reduction of blood Glutamate concentration by renal replacement therapy	72 hours
Secondary	number of participants with abnormal outcome parameters		up to 14 days